目的 探讨女性型脱发患者相关实验室指标对脱发的影响。 方法 选取2022年11月至2023年11月就诊于杭州市第一人民医院医疗美容科门诊的女性型脱发患者作为研究组，选取同期该院体检中心与研究组年龄相当的健康女性作为对照组。记录受试者的一般情况，并对受试者行毛发镜检测，以排除其他模式脱发。从实验室检测项目中选择具有代表性的指标做进一步分析，包括睾酮、硫酸脱氢表雄酮、促甲状腺激素、25-羟维生素D、血清铁蛋白，并根据25-羟维生素D水平计算缺乏(<20 ng/ml)比例(缺乏例数/各组总例数×100%)。计数资料以例(百分数)表示，组间比较采用卡方检验；正态分布计量资料以±s表示，组间比较采用独立样本t检验，非正态分布计量资料以M(Q1，Q3)表示，组间比较采用Wilcoxon秩和检验；应用多元logistic回归分析女性型脱发的影响因素。P<0.05为差异有统计学意义。 结果 2组均纳入37例女性受试者，其中研究组年龄为(28.8±1.3)岁，对照组为(29.6±0.9)岁(t＝0.49，P＝0.625)；研究组体重指数为(22.8±0.4) kg/m2，对照组为(23.5±0.3) kg/m2(t＝1.26，P＝0.211)。研究组睾酮水平为0.58(0.49，0.79) nmol/L，对照组为0.54(0.50，0.78) nmol/L(Z＝1.42，P＝0.157)；研究组硫酸脱氢表雄酮水平为6.21(5.18，9.60) μmol/L，对照组为6.20(5.20，9.34) μmol/L(Z＝2.75，P＝0.006)；研究组促甲状腺激素水平为2.56(1.55，3.66) mU/L，对照组为1.49(1.05，2.65) mU/L(Z＝2.51，P＝0.012)；研究组25-羟维生素D水平为15.44(11.80，21.20) ng/ml，对照组为20.32(12.07，21.20) ng/ml (Z＝2.30，P＝0.021)，研究组25-羟维生素D缺乏比例为64.9%(24/37)，高于对照组的40.5%(15/37)(χ2＝4.39，P＝0.036)；研究组血清铁蛋白水平为64.44(39.47，133.45) μg/L，对照组为67.75(52.63，143.83) μg/L(Z＝0.70，P＝0.484)。多元logistic回归分析结果显示，硫酸脱氢表雄酮水平增高、促甲状腺激素水平升高、25-羟维生素D水平低下会增加女性型脱发的风险(P均<0.05)。 结论 硫酸脱氢表雄酮、促甲状腺激素、25-羟维生素D水平的异常可能增加女性型脱发疾病风险。 Objective To investigate the effect of laboratory indicators on hair loss in patients with female pattern hair loss (FPHL). Methods Patients with FPHL who visited the Outpatient Clinic of the Department of Medical Aesthetics in Hangzhou First People’s Hospital from November 2022 to November 2023 were selected as the study group, and healthy women who matched the age of the study group in the physical examination center during the same period were selected as the control group. The general information of the patient was recorded, and was also tested by trichoscopy to rule out other patterns of alopecia. Representative indicators including testosterone, dehydroepiandrosterone sulfate(DHEA-S), thyroid-stimulating hormone, 25-hydroxyvitamin D, and serum ferritin were selected from laboratory tests for further analysis. Otherwise, the proportion of deficiency in vitamin D(<20 ng/ml) was calculated based on 25-hydroxyvitamin D levels (number of deficiency cases/total number of cases in each group×100%). Count data were presented as samples (percentages), and chi-square test was used for comparison between groups. Normally distributed continuous data were presented with Mean±SD, independent samplest-test was used for comparison between groups, M(Q1, Q3) was used for non-normally distributed continuous data, and Wilcoxon rank-sum test was used for comparison between groups. Multivariate logistic regression was used to analyze the influencing factors of FPHL. P<0.05 was statistically significant. Results A total of 37 patients were selected in both groups. The mean age was (28.8±1.3) years in the study group and (29.6±0.9) years in the control group (t=0.49, P=0.625). The body mass index was (22.8±0.4) kg/m2 in the study group, and (23.5±0.3) kg/m2 in the control group (t=1.26, P=0.211). The testosterone level was 0.58 (0.49, 0.79) nmol/L in the study group, and 0.54 (0.50, 0.78) nmol/L in the control group(Z=1.42, P=0.157). The level of DHEA-S was 6.21 (5.18, 9.60) μmol/L in the study group, and 6.20 (5.20, 9.34) μmol/L in the control group ( Z=2.75, P=0.006). The level of thyroid-stimulating hormone was 2.56 (1.55, 3.66) mU/L in the study group and 1.49 (1.05, 2.65) mU/L in the control group (Z=2.51, P=0.012). The level of 25-hydroxyvitamin D was 15.44 (11.80, 21.20) ng/ml in the study group, and the level of 25-hydroxyvitamin D was 20.32 (12.07, 21.20) ng/ml in the control group (Z=2.30, P=0.021), and the proportion of 25-hydroxyvitamin D deficiency in the study group was 64.9% (24/37), which was higher than that in the control group [40.5% (15/37)] (χ2=4.39, P=0.036). The serum ferritin level was 64.44 (39.47, 133.45) μg/L in the study group and 67.75 (52.63, 143.83) μg/L in the control group ( Z=0.70, P=0.484). The results of multivariate logistic regression analysis showed that the risk of FPHL was increased by the high level of DHEA-S and thyroid-stimulating hormone, and the low level of 25-hydroxyvitamin D (all P<0.05). Conclusion Abnormal level of DHEA-S, thyroid-stimulating hormone, and 25-hydroxyvitamin D may be risk factors for FPHL.
Analysis of laboratory indicators related to female pattern hair loss
Objective To investigate the effect of laboratory indicators on hair loss in patients with female pattern hair loss (FPHL). Methods Patients with FPHL who visited the Outpatient Clinic of the Department of Medical Aesthetics in Hangzhou First People’s Hospital from November 2022 to November 2023 were selected as the study group, and healthy women who matched the age of the study group in the physical examination center during the same period were selected as the control group. The general information of the patient was recorded, and was also tested by trichoscopy to rule out other patterns of alopecia. Representative indicators including testosterone, dehydroepiandrosterone sulfate(DHEA-S), thyroid-stimulating hormone, 25-hydroxyvitamin D, and serum ferritin were selected from laboratory tests for further analysis. Otherwise, the proportion of deficiency in vitamin D(<20 ng/ml) was calculated based on 25-hydroxyvitamin D levels (number of deficiency cases/total number of cases in each group×100%). Count data were presented as samples (percentages), and chi-square test was used for comparison between groups. Normally distributed continuous data were presented with Mean±SD, independent samplest-test was used for comparison between groups, M(Q1, Q3) was used for non-normally distributed continuous data, and Wilcoxon rank-sum test was used for comparison between groups. Multivariate logistic regression was used to analyze the influencing factors of FPHL. P<0.05 was statistically significant. Results A total of 37 patients were selected in both groups. The mean age was (28.8±1.3) years in the study group and (29.6±0.9) years in the control group (t=0.49, P=0.625). The body mass index was (22.8±0.4) kg/m2 in the study group, and (23.5±0.3) kg/m2 in the control group (t=1.26, P=0.211). The testosterone level was 0.58 (0.49, 0.79) nmol/L in the study group, and 0.54 (0.50, 0.78) nmol/L in the control group(Z=1.42, P=0.157). The level of DHEA-S was 6.21 (5.18, 9.60) μmol/L in the study group, and 6.20 (5.20, 9.34) μmol/L in the control group ( Z=2.75, P=0.006). The level of thyroid-stimulating hormone was 2.56 (1.55, 3.66) mU/L in the study group and 1.49 (1.05, 2.65) mU/L in the control group (Z=2.51, P=0.012). The level of 25-hydroxyvitamin D was 15.44 (11.80, 21.20) ng/ml in the study group, and the level of 25-hydroxyvitamin D was 20.32 (12.07, 21.20) ng/ml in the control group (Z=2.30, P=0.021), and the proportion of 25-hydroxyvitamin D deficiency in the study group was 64.9% (24/37), which was higher than that in the control group [40.5% (15/37)] (χ2=4.39, P=0.036). The serum ferritin level was 64.44 (39.47, 133.45) μg/L in the study group and 67.75 (52.63, 143.83) μg/L in the control group ( Z=0.70, P=0.484). The results of multivariate logistic regression analysis showed that the risk of FPHL was increased by the high level of DHEA-S and thyroid-stimulating hormone, and the low level of 25-hydroxyvitamin D (all P<0.05). Conclusion Abnormal level of DHEA-S, thyroid-stimulating hormone, and 25-hydroxyvitamin D may be risk factors for FPHL.
万方数据
